Merck & Co., in the Whitehouse Station section of Readington, announced today an agreement with Samsung Bioepis Co. Ltd. to develop and commercialize several biosimilar candidates.
Under the agreement, Samsung Bioepis, of Seoul, South Korea, will be responsible for preclinical and clinical development, process development and manufacturing, clinical, trials and registration. Merck will be responsible for commercialization.
Samsung Bioepis will receive an upfront payment from Merck, product supply income and will be eligible for additional payments associated with certain clinical and regulatory milestones. Further financial terms were not disclosed.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy